Indanorex

Indanorex

SCHEMBL162653

CCC(N)C1(O)Cc2ccccc2C1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 2/20 0.38
DPP9 Q86TI2 2/20 0.38
DPP7 Q9UHL4 2/20 0.38
DPP4 P27487 1/20 0.38
HTR2A P28223 2/20 0.35
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
ADRA1B P35368 1/20 0.33
LMNA P02545 2/20 0.32
MME P08473 1/20 0.32
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
OPRL1 P41146 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
SLC6A2 P23975 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6263925 0.78 LMNA (0.38) DPP8DPP9DPP7DPP4ADRA2A
SCHEMBL11875860 0.73 ALOX15 (0.38) SLC6A4SLC6A3
SCHEMBL20201328 0.73 OPRM1 (0.43) HTR2AOPRM1OPRD1OPRK1OPRL1
Hydrochloric Acid SCHEMBL11874397 0.72 ALOX15 (0.37) SLC6A4SLC6A3ADRA2A
SCHEMBL26781436 0.69
SCHEMBL26781438 0.69
Hydrochloric Acid SCHEMBL23909499 0.67 SLC6A4 (0.31) SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL23909501 0.67 SLC6A4 (0.31) SLC6A4SLC6A3
SCHEMBL27499227 0.67 ADRA2A (0.40) ADRA2AADRA2BADRA2CADRA1BLMNA
SCHEMBL11128739 0.65 PDK2 (0.40) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200060997-A1 TARR Receptor Agonists for Sexual Dysfunction JOHN MCCOY 2020-02-27 US claimed
EP-3366306-A2 USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO Istanbul Universitesi Rektorlugu (TR) 2018-08-29 EP claimed
EP-3351262-A1 CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO Istanbul Universitesi Rektorlugu (TR) 2018-07-25 EP claimed
US-20160000815-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CT HOLDINGS PTY LTD (AU) 2016-01-07 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
EP-2729216-A1 PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS Gosforth Centre (Holdings) Pty Ltd (AU) 2014-05-14 EP claimed
WO-2013007698-A1 PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2013-01-17 WO claimed
JP-2011529923-A 2011-12-15 JP claimed
CN-102170874-A Compositions and methods for treating psychiatric disorders GOSFORTH CT HOLDINGS PTY LTD 2011-08-31 CN claimed
US-20110207718-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) 2011-08-25 US claimed
EP-2331088-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS Gosforth Centre (Holdings) Pty Ltd (AU) 2011-06-15 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
WO-2010015029-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2010-02-11 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2026106796-A1 SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS FOLLEA INTERNATIONAL (US) 2026-05-21 WO disclosed
US-3885045-A Therapeutic composition containing 1-(2-hydroxy-2-indanyl)-propylamine LOGEAIS LABOR JACQUES 1975-05-20 US disclosed
US-3885045-A Therapeutic composition containing 1-(2-hydroxy-2-indanyl)-propylamine LOGEAIS LABOR JACQUES 1975-05-20 US disclosed